Please use this identifier to cite or link to this item:
|Title:||Drug–drug interactions in patients receiving hematopoietic stem cell transplantation|
|Authors:||Pejcic, Ana |
|Abstract:||© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Recipients of hematopoietic stem cell transplantation (HSCT) are exposed to numerous drugs in both pre- and post-transplantation period, which creates an opportunity for drug–drug interactions (DDIs); if clinically relevant DDIs happen, the risk of adverse treatment outcomes is increased. Areas covered: This review is focused on DDIs in recipients of HSCT that were observed and published as clinical trials, case series or case reports. Relevant publications were found by the systematic search of the following online databases: MEDLINE, SCOPUS, EBSCO, and SCINDEX. Expert opinion: The most important DDIs involve cytostatic or immunosuppressant drug on one side, and antimicrobial drugs on the other. The majority of clinically relevant interactions have pharmacokinetic character, involving drug metabolizing enzymes in the liver. Antifungal azoles inhibit metabolism of many cytostatic and immunosuppressant drugs at cytochromes and increase their plasma concentrations. Macrolide antibiotics and fluoroqunolones should be avoided in HSCT recipients, as they have much larger potential for DDIs than other antibiotic groups. HSCT recipients increasingly receive new immunomodulating drugs, and further observational studies are needed to reveal unsuspected DDIs with clinical relevance.|
|Appears in Collections:||Faculty of Medical Sciences, Kragujevac|
Files in This Item:
|29.86 kB||Adobe PDF|
Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.